Alfuzosin
alpha-Adrenergic Blocker — GENITO URINARY SYSTEM AND SEX HORMONES
Also known as: alfuzosin HCl, alfuzosin hydrochloride, SL 77, xatral
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Alfuzosin is an ofp drug in the alpha-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2003. Its mechanism of action is classified as Adrenergic alpha-Antagonists. DrugCentral lists 7 molecular targets, including ADRA1B, Adra1d and ADRA1D. Recorded indications include Benign prostatic hyperplasia.
- Approval status: ofp (first approved 2003 by the FDA).
- Drug class: alpha-Adrenergic Blocker.
- Mechanism of action: Adrenergic alpha-Antagonists.
- Molecular targets: ADRA1B, Adra1d, ADRA1D and ADRA1A (7 listed in DrugCentral).
- Indications: Benign prostatic hyperplasia.
- ATC code: G04CA01 (Alpha-adrenoreceptor antagonists).
- Molecular formula: C19H27N5O4; molecular weight 389.46 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Benign prostatic hyperplasia
Contraindications (13)
- Acute nephropathy
- Angina pectoris
- Cataract surgery
- Congenital long QT syndrome
- Disease of liver
- Hepatic failure
- Intraoperative floppy iris syndrome
- Low blood pressure
- Micturition syncope
- Orthostatic hypotension
- Progressive Angina Pectoris
- Prolonged QT interval
- Torsades de pointes
Mechanism & targets
| Mechanism of action (MoA) | Adrenergic alpha-Antagonists |
|---|---|
| Established pharmacologic class | alpha-Adrenergic Blocker |
Molecular targets (7)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Alpha-1B adrenergic receptor | ADRA1B | antagonist | Ki 8.55 |
| Alpha-1D adrenergic receptor | Adra1d | unknown | Ki 8.46 |
| Alpha-1D adrenergic receptor | ADRA1D | antagonist | Ki 8.44 |
| Alpha-1A adrenergic receptor | ADRA1A | antagonist | Ki 8.09 |
| Acetylcholinesterase | ACHE | unknown | IC50 7.75 |
| Alpha-1A adrenergic receptor | ADRA1A | unknown | Ki 7.64 |
| Solute carrier family 22 member 1 | SLC22A1 | unknown | IC50 4.83 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2003-06-12 | FDA | — | COVIS PHARMA SARL |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
G04CA01 | GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists |
G04CA51 | GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Acute kidney injury | 363.1 |
| Drug interaction | 243.0 |
| Drug dispensed to wrong patient | 194.5 |
| Hypotension | 189.0 |
| Syncope | 176.9 |
| Cholestasis | 162.5 |
| Orthostatic hypotension | 154.5 |
| Agranulocytosis | 145.1 |
| Antimicrobial susceptibility test resistant | 132.7 |
| Minimum inhibitory concentration | 128.8 |
| Wrong patient received product | 115.8 |
| Fall | 112.7 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Alfuzosin is on its molecule page.
| Molecular formula | C19H27N5O4 |
|---|---|
| Molecular weight | 389.46 g/mol |
| CAS number | 81403-80-7 |
| InChIKey | WNMJYKCGWZFFKR-UHFFFAOYSA-N |
| PubChem CID | 2092 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Alfuzosin used for?
DrugCentral lists the following indications for Alfuzosin: Benign prostatic hyperplasia.
How does Alfuzosin work?
Alfuzosin is classified as Adrenergic alpha-Antagonists; its molecular targets in DrugCentral include ADRA1B (antagonist), Adra1d, ADRA1D (antagonist) and ADRA1A (antagonist).
When was Alfuzosin first approved?
Alfuzosin was first approved by the FDA in 2003.
What drug class does Alfuzosin belong to?
Alfuzosin is in the alpha-Adrenergic Blocker class.
What is the chemical formula of Alfuzosin?
Alfuzosin has the molecular formula C19H27N5O4 and a molecular weight of 389.46 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 115 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1723 — compound record and bioactivity
- PubChem CID 2092 — chemical identifiers
- DrugBank DB00346 — drug record
- FDA UNII 90347YTW5F — substance identity
- DailyMed: FDA labels for Alfuzosin — current prescribing information (label search)
- UniProt P35368 (ADRA1B) — target protein
- UniProt P25100 (ADRA1D) — target protein
- UniProt P35348 (ADRA1A) — target protein
- UniProt P22303 (ACHE) — target protein
- UniProt O15245 (SLC22A1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.